Mal wieder was von Supergen:

Tuesday February 20, 9:03 am Eastern Time

Press Release

SOURCE: SuperGen Inc.

SuperGen Completes Enrollment in Phase III Clinical
Study of Rubitecan as Treatment for Pancreatic Cancer

Closing of 'Gemzar refractory' study paves way for data analysis necessary for filing of New Drug
Application

DUBLIN, Calif., Feb. 20 /PRNewswire/ -- SuperGen Inc. (Nasdaq: SUPG & SUPGZ) announced today that it has
completed patient enrollment in the Phase III clinical study that the company is conducting of its oral chemotherapy compound
rubitecan as a treatment for pancreatic cancer in Gemzar refractory patients.

The 'Gemzar refractory' study enrolled more than 400 patients diagnosed with pancreatic cancer, who subsequently failed
therapy with Gemzar (Gemcitabine, Eli Lilly). Each patient was then randomized to either rubitecan or 5-FU, another
chemotherapeutic agent. Enrollment and testing commenced at over 150 medical centers around the United States.

Two additional studies -- 'chemotherapy nave', where patients who have had no prior chemotherapy are randomized to either
rubitecan or Gemzar; and 'chemotherapy refractory', where patients who have failed multiple types of chemotherapy are
randomized to either rubitecan or the next best therapy -- are 90 percent full and continuing to enroll patients.

``The completion of enrollment in our Phase III refractory clinical study is a major accomplishment,'' said Dr. Joseph Rubinfeld,
chairman and chief executive officer of SuperGen. `` During the first half of 2001, our experienced management team will
analyze literally thousands of pages of data and then begin the process of compiling a New Drug Application (NDA), which we
plan to submit in the latter half of 2001.''

Based in Dublin, California, SuperGen is a pharmaceutical company dedicated to the development and commercialization of
products intended to treat life-threatening diseases, particularly cancer.

Reicht immerhin für eine phantastische Kurssteigerung von knapp 2%!!!


Gruß Dampf

Und das als Biotechunternehmen.

Friday March 23, 9:15 am Eastern Time

Press Release

SOURCE: SuperGen Inc.

SuperGen's Board Authorizes Additional One Million
Share Stock Repurchase Program

DUBLIN, Calif., March 23 /PRNewswire/ -- SuperGen Inc. (Nasdaq: SUPG & SUPGZ)
announced today that its board of directors has authorized an additional stock repurchase
program of one million shares of the Company's common stock. On September 28, 2000,
the board of directors authorized the repurchase of one million shares of common stock.

``Shares of our common stock have not been immune to our economy's volatility,'' said Dr.
Joseph Rubinfeld, chairman and chief executive officer of SuperGen. ``However, the
fundamentals of our company, including our broad product portfolio of three 'franchise
compounds' -- rubitecan, decitabine and Nipent® -- as well as the extensive experience of
our seasoned management team, remain intact.

``As such, the directors have strongly agreed that repurchasing SuperGen shares at this time
is a very responsible use of the company's substantial cash resources. Our financial position
continues to be sufficiently strong to allow for both stock repurchase and continued
execution of our strategy to be a leader in oncology. Above all, our decision to implement
this program underscores both our belief that SuperGen's shares are substantially
undervalued, but also our pledge to enhance shareholder value.''

SuperGen will use existing cash to finance these repurchases. The Company expects such
purchases to be effected from time to time in the open market, in private transactions or
otherwise, subject to market conditions. No assurance can be given as to the time period
over which the shares will be repurchased or as to whether and to what extent the share
repurchases will be consummated.

Gruß Dampf

patients studied with high-risk MDS, especially patients with the worse prognosis.

In December 2000, at the 42nd Annual Meeting of the American Society of Hematology
(ASH), in San Francisco, Michael Lubbert of the University of Freiberg (Germany) Medical
Center presented data on a study of 124 ``high-risk'' patients with MDS and reported that,
``Decitabine had anti-leukemic activity... in 50 percent of patients with myelodysplastic
syndrome.''

Also at the ASH meeting, Donald Lavelle, M.D., University of Illinois (Chicago), reported
preclinical data that demonstrated decitabine's mechanism of action occurs through the mediation of gene expression, which in
turn potentiates the effect of alpha interferon in multiple myeloma. These data support the potential clinical use of low-dose
decitabine as a gene therapeutic induction agent in addition to its role as a traditional cytotoxic agent.

Studies Show SuperGen's Rubitecan Has Anti-Tumor
Activity Against Melanoma, Prostate and Lung Cancers

Data presented at annual meeting of American Association for Cancer Research (AACR)

DUBLIN, Calif., March 28 /PRNewswire/ -- SuperGen Inc. (Nasdaq: SUPG & SUPGZ) announced today that its novel drug
compound, rubitecan -- which is now in the final stages of Phase III clinical testing as an oral therapy against pancreatic cancer
-- showed anti-tumor activity against melanoma, prostate cancer and lung cancer, in three separate studies. Data from three
studies was recently presented at the 92nd Annual Meeting of the American Association for Cancer Research in New Orleans.

The first study, under lead investigator Dr. Devasis Chatterjee of Brown University, Providence, R.I., concluded that raf kinase
inhibitory protein (RKIP), when added to 9-NC (rubitecan), plays an integral function ``in the sensitization of 9-NC responsive
and resistant prostate cancer cells to apoptosis induction (cell death).''

The second study, under lead investigator Dr. Howard Sands of Morrisville, N.C.-based Piedmont Research Center, showed
that a proprietary intravenous formulation of 9-NC (rubitecan) had ``outstanding antitumor activity against human melanoma
xenografts in nude mice. Furthermore, we now are investigating whether the I.V. activity of 9-NC extends to other human
tumor xenografts, and how its spectrum of activity compares to that of oral preparation.''

The third study, under lead investigator Dr. Nadezhda V. Koshkina of Baylor College of Medicine, Houston, demonstrated
that an inhaled liposome formulation of 9-NC (rubitecan) and paclitaxel drugs resulted in ``significantly higher concentrations of
9-NC and paclitaxel'' in the lungs of treated mice. Our findings support the continued evaluation of more effective methods for
lung cancer treatment by using an aerosol delivery system,`` concluded Dr. Koshkina. Inhaled rubitecan is currently in Phase
I/II clinical development.

Also presented at AACR were results from a preclinical study showing that SuperGen's anticancer compound decitabine
increased the gene expression of four lung cancer cell lines, thus significantly lowering their growth rates. Decitabine, which has
a unique mechanism of action - the hypomethylation of DNA - is in Phase III clinical development for myelodysplastic
syndrome and Phase I/II clinical development for stage IV non-small cell lung cancer, as well as and sickle cell anemia.


Gruß Dampf